Chief Biohacker TrueMedX & Neighborly Wellness | Regulatory Consultant & Expert Speaker | Contributor, American Journal of Endocannabinoid Medicine | Host of 'Chip Talks' Podcast | Chickasaw Citizen
Not really. My patent #10,646,535 proves an engineering method which can be used as an intellectual property fence to protect development up botanical new drug. Botanical new drug will be where most of this development occurs. I do agree that cannabis will be somewhat of a novelty soon as we begin REAL research and REAL study of the endocannabinoid system. Why develop with cannabis when you can develop with endocannabinoids? There is no doubt the world changed on 4/30/24...
Cannabis Science and Genetics 🧬 Co-Founder and CSO, S3 🧬 Gene Editing 🧬 BetterCannabisThroughScience Consulting 🧬 Molecular Biologist 🧬 Outdoors Enthusiast
I'm going to continue beating this dead horse. The Cannabis plant is safe from Pharma. Pharma wants single molecules. Novel. Selective. Potent. Patentable. Exhibit A: A new preprint from Swiss pharma giant Roche (and a collaborator from NIH). They describe RNB-61, a new CB2 receptor selective agonist. It is 6000-fold selective over CB1. #BetterCannabisThroughScience Preprint in comments
